Masimo Co. (NASDAQ:MASI) Shares Sold by Laurus Investment Counsel Inc.

Laurus Investment Counsel Inc. reduced its holdings in shares of Masimo Co. (NASDAQ:MASI) by 7.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,710 shares of the medical equipment provider’s stock after selling 630 shares during the period. Laurus Investment Counsel Inc.’s holdings in Masimo were worth $904,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. American Century Companies Inc. grew its stake in Masimo by 2.3% during the 1st quarter. American Century Companies Inc. now owns 8,799 shares of the medical equipment provider’s stock valued at $1,281,000 after purchasing an additional 194 shares during the last quarter. Great West Life Assurance Co. Can boosted its stake in shares of Masimo by 24.0% in the first quarter. Great West Life Assurance Co. Can now owns 59,540 shares of the medical equipment provider’s stock worth $9,049,000 after buying an additional 11,543 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Masimo by 3.9% in the first quarter. Dimensional Fund Advisors LP now owns 226,526 shares of the medical equipment provider’s stock worth $32,977,000 after buying an additional 8,501 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of Masimo by 1,011.6% in the first quarter. Canada Pension Plan Investment Board now owns 2,390 shares of the medical equipment provider’s stock worth $348,000 after buying an additional 2,175 shares during the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of Masimo by 1.5% in the first quarter. Vanguard Group Inc. now owns 4,775,660 shares of the medical equipment provider’s stock worth $695,050,000 after buying an additional 71,918 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MASI has been the topic of a number of recent analyst reports. StockNews.com downgraded Masimo from a “hold” rating to a “sell” rating in a research report on Thursday, March 21st. BTIG Research increased their price target on Masimo from $145.00 to $166.00 and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC cut Masimo from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Wells Fargo & Company raised Masimo from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $117.00 to $160.00 in a report on Monday. Finally, Stifel Nicolaus increased their target price on Masimo from $125.00 to $148.00 and gave the company a “hold” rating in a report on Monday. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $134.29.

Masimo Price Performance

NASDAQ:MASI opened at $144.48 on Thursday. Masimo Co. has a one year low of $75.22 and a one year high of $198.00. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.22 and a current ratio of 2.18. The stock has a market cap of $7.64 billion, a PE ratio of 95.68 and a beta of 0.95. The stock has a 50 day moving average price of $131.76 and a 200 day moving average price of $109.26.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, February 27th. The medical equipment provider reported $1.25 EPS for the quarter, topping the consensus estimate of $0.82 by $0.43. The firm had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. Masimo had a return on equity of 13.77% and a net margin of 3.98%. Masimo’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the firm posted $1.32 EPS. Equities research analysts expect that Masimo Co. will post 3.51 EPS for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.